Description: Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
Home Page: www.cybin.com
CYBN Technical Analysis
100 King Street West
Toronto,
ON
M5X 1C9
Canada
Phone:
908 764 8385
Officers
| Name | Title |
|---|---|
| Mr. Eric So L.L.B., LLB | Co-Founder, Pres & Exec. Chairman |
| Mr. Douglas L. Drysdale | Chief Exec. Officer |
| Mr. Paul Glavine | Co-Founder, Chief Growth Officer & Director |
| Mr. John Kanakis | Co-Founder |
| Mr. Greg Cavers | Chief Financial Officer |
| Mr. Aaron Bartlone | Chief Operating Officer |
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer |
| Ms. Leah Gibson | VP of Investor Relations & Strategic Communications |
| Ms. Lori Challenger | Chief Compliance, Ethics & Admin. Officer |
| Mr. Gabriel Fahel | Chief Legal Officer & Corp. Sec. |
Exchange: NYSE MKT
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1616 |
| Price-to-Sales TTM: | 278.2498 |
| IPO Date: | 2019-09-13 |
| Fiscal Year End: | March |
| Full Time Employees: | 50 |